Female sex hormones may be involved in the etiology of human meningioma. Following the first report in 1979, on the putative presence of oestrogen receptors (ER) in human meningiomas (Donnell et al., 1979) , several research groups, including our own (Blankenstein et al., 1983; Martuza et al., 1985) have tried to confirm these findings. Using Scatchard plot analysis (Blaauw et al., 1986) or enzyme immunoassay (Blankenstein et al., 1987 ) the majority of meningiomas were found to be ER negative. The same experiments revealed that meningiomas contain high amounts of progestin receptors (PR) . Since in classical female sex steroid target tissues like breast and uterus, the synthesis of PR is ER dependent the finding that (at the protein level at least) meningiomas are rich in PR, yet virtually devoid of ER initiated further research.
We recently reported on the detection of mRNA coding for the wild type receptor by using the reversed-transcriptase-PCR technique (Koehorst et al., 1992) . Apart from the wild type (wt) mRNA we also found two alternatively spliced mRNA's. One variant is missing exon 4 and the other is missing exon 7 (Koehorst et al., 1993) .
The present study was designed to evaluate the presence in meningiomas of ER or ER-like proteins which could induce PR synthesis. We hypothesised that if the ER (at concentrations below the detection limit of the conventional receptor assay) or control for ERE binding.
To confirm the integrity of the protein isolated from the tumours, a band shift assay was performed using a oligonucleotide which contained the Spl binding consensus sequence (5'-CAAAGTCTGGGCGGGCCGATCAAG-'3; consensus is underlined). For the competition binding analysis in which the specificity of the ERE was proven, a oligonucleotide was used which contained the consensus of the progesterone responsive element (PRE)(5'-CCAAA-GTCAGAACACAGTGTTCTGATCAAG-3'; palindrome is underlined and differences with palindrome of ERE are in bold underlined). 1989; Klock et al., 1987) . The specificity of binding of the ERE oligonucleotides to ER in crude, high salt extracts from MCF7 and meningioma is shown in Figure 1 . The intensity of the ER-ERE complex decreases with increasing ratios of unlabelled/labelled ERE, while the intensity of the ER-ERE complex is unaffected with increasing molar excess of PRE (Figure la and b) . When MCF7 cytosol was run together with the meningioma sample a single, prominent band co-migrating with that obtained from MCF7 whole cell extract was observed. We attribute this result to the presence of ER or an ER-like protein in the meningioma tissue.
To identify the ER in the ER-ERE complex, cytosols were incubated with the anti-ER monoclonal antibody ER-P3 1 (MEDAC, Hamburg, Germany). This antibody inhibits the binding to the ERE of the ER from MCF7 cells as well as the ER-like protein in the two meningiomas and the ER in solid breast tumours (Figure 2 ).
After we had proven the specificity of this ERE oligonucleotide under our experimental conditions, we tested 15 meningiomas with different ER and PR concentration. In all meningiomas but one, including the meningiomas which were ER negative in the ligand binding assay, we could detect a protein which can bind to ERE oligonucleotide (Figure 3, upper panel) . The ERE-protein complex from the meningiomas co-migrates with the MCF7 ER-ERE complex even in gels run for longer times (data not shown). To check the integrity of the isolated protein all the meningiomas were tested for SpI binding and all except one were found to be positive (Figure 3, lower (Koehorst et al., 1992) . Besides the wild type transcript two variants were detected, one missing exon 7 and the other missing exon 4 (Koehorst et al., 1993) . If the wt transcript or the variants are responsible for the PR synthesis, we hypothesise that a protein has to be present which can bind to an ERE.
We analysed DNA-binding activity to the ERE in human meningiomas by a gel mobility assay. The promotor regions of the PR gene are under investigation to define the functional ERE in this gene. So far two functional promotor regions have been described to be important for the induction of PR synthesis by ER. These two regions showed oestrogen inducibility in transient co-transfection experiments with vectors expressing the human ER, although no 'classical' ERE was detected in these promotor regions (Kastner et al., 1990 decided to use a 'classical' ERE from the Xenopus vitellogenin A2 gene. This element has been shown to be specific in several band-shift experiments performed by other groups (Klein-Hitpass et al., 1989) . We used MCF7 cells as a positive control and demonstrated that the ER-ERE complex derived from meningioma extracts co-migrated with the complex obtained from whole cell extracts of MCF7 cells. The anti-ER monoclonal antibody ER-P3 1 was able to specifically block ER-ERE complex formation, demonstrating the presence of ER in the complex from MCF7 cells, meningiomas and solid breast cancer derived cytosol ( Figure  2 ). This antibody has been used before in immunohistochemistry (Wilkinson et al., 1988) . ER-P31 gives intense nuclear staining on frozen sections of breast carcinoma. Binding of the antibody to ER was confirmed by displacement assays of the receptor on a sucrose gradient (Wilkinson et al., 1988; Wong et al., 1991) . The epitope which is recognised by ER-P31 is located in the A/B domain of the receptor. Since this is the variable part of the receptor recognition of ERR-1 or ERR-2 is very unlikely. This antibody inhibits the DNA binding activity of ER. Therefore in the present experiments incubation with antibody was carried out first, followed by incubation with the ERE. If incubation with the ERE is performed first, the antibody hardly interferes with DNA binding of ER. Following binding to the ERE the epitope on the ER is probably no longer accessible to the antibody. Based on the considerations above, we conclude that the ERE used is specific.
We tested 15 meningiomas for the presence of proteins binding to the ERE. The receptor phenotype of these meningiomas ranged from ER/PR positive, ER-negative/PRpositive to ER/PR negative. All but one of the meningiomas were positive for ER-ERE binding, including the ER/PR negative meningiomas (Figure 3, upper panel) . This suggests that the protein detected is by itself not sufficient to induce PR synthesis in meningiomas.
It is tempting to speculate that this ER or ER-like protein plays a role in the development and growth of the meningioma and biosynthesis of PR. To test the tumour specificity of the ERE binding, meningiomas and normal meninges from two patients were used. The two meningiomas were positive for ER-ERE binding and also positive for Spl binding (Figure 3) . The normal meninges however were negative for both. This can be attributed to the fact that normal meningeal tissue is a quiescent tissue. This is confirmed by the fact that we also were not able to isolate any intact mRNA from the normal meninges. Thus the normal meninges cannot be used as a control in this assay and no conclusions can be drawn about the tumour specificity of the ER-ERE binding.
The band shift assay results shown here apparently are in disagreement with those from the ligand binding assay obtained in the past. From experiments with breast tumours it is known however that the band shift assay is not always in agreement with the ligand binding assay. Foster et al. (1991) tested 79 breast tumours of which 55 showed that the band shift assay was in agreement with the hormone-binding assay. In 13 tumours the hormone binding assay was negative whereas the band shift assay was positive. In two cases a ER-negative/PR-positive tumour was tested, in both cases the band shift assay was positive (Foster et al., 1991) . These two cases have resemblance with the phenotype of meningiomas which are mostly also ER-negative/PR-positive.
In meningiomas an ER or ER-like protein is detectable by the band shift assay but not detectable by ligand-binding (Blaauw et al., 1986) or by enzyme immunoassay (Blankenstein et al., 1987) . This may be due to the sensitivity of the assay (Scott et al., 1991) .
Another explanation could be a mutation in the hormonebinding domain of the ER so that such an ER variant would not be detected by the ligand binding assay and probably also not in the immunoassay. For example in ER-/PR+ breast tumours an ER variant was detected missing exon 5. This variant was constitutively active in a trans-activation assay . We detected in meningiomas two variant ER mRNA species (Koehorst et al., 1993) . One variant with a major deletion in the ligand binding domain was an alternatively spliced product missing exon 7. This variant has no hormone independent transcriptional activity as shown by McGuire et al. (1991) . Therefore this variant can probably not account for the apparently autonomous PR synthesis in meningiomas. The variant missing exon 4 codes for ER missing amino acid 254-365. Exon 4 includes the last part of the DNA binding domain, the hinge region and the first hundred amino acids of the ligand binding domain. The two zinc fingers of the DNA binding domain are intact so DNA binding can probably occur but no oestradiol will be bound by this variant because a great part of the ligand binding domain is missing. In addition, the highly positively charged region situated between amino acid 251 and 271 is missing. This sequence is very important for the formation of the non-DNA binding 8-9 S ER complexes, which bind heat shock protein 90 (hsp 90) (Chambraud et al., 1990) . A variant missing amino acids 251-271 such as the variant missing exon 4 can probably not bind hsp 90 and therefore is always in the 4-5 S DNA binding form. This variant could play a role but whether it is capable of transactivation as well as its relationship to the ER-like protein described here remain to be investigated.
